CSBio CSBio

X
[{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"OMass Therapeutics"},{"orgOrder":0,"company":"LoQus23 Therapeutics","sponsor":"Dementia Discovery Fund","pharmaFlowCategory":"D","amount":"$9.4 million","upfrontCash":"Undisclosed","newsHeadline":"LoQus23 Therapeutics Exits Stealth with \u00a311.5 Million Seed Financing From the Dementia Discovery Fund and Novartis Venture Fund","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"LoQus23 Therapeutics"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"GV","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"OMass Therapeutics"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bit.bio Launches Huntington\u2019s Disease Human Cell Model","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bit Bio"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"bit.bio Presents Data at ISSCR Demonstrating Their Platform Capability to Create Any Human Cell","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bit Bio"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Poolbeg Partners with a Nasdaq-Listed Biopharma","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Poolbeg Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the collaboration, the Company will produce a prototype drug utilising Poolbeg's licensed oral delivery technology. Poolbeg believes that this technology can help to optimise the delivery of its partner's novel drug to its ideal site of therapeutic action.

            Lead Product(s): Undisclosed

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Vaccine

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            These precisely reprogrammed cell types are generated with the company’s precision cellular reprogramming technology opti-oxTM that enables unlimited batches of any human cell to be manufactured consistently at scale.

            Lead Product(s): Undisclosed

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            First neurodegenerative disease model launched from bit.bio's new ioDisease Model portfolio. Accurately replicates Huntington's disease genotype in human cells, setting a new standard in cell models for drug discovery.

            Lead Product(s): Undisclosed

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Proceeds from the financing will be used to advance OMass’s portfolio towards clinical trials. This includes the development of an insurmountable antagonist of the MC2 receptor for congenital adrenal hyperplasia.

            Lead Product(s): Undisclosed

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: GV

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing April 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will enable LoQus23 to identify a small molecule drug candidate for the company's lead MMR target and explore other MMR proteins for their role in somatic instability in TRDs.

            Lead Product(s): Undisclosed

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Dementia Discovery Fund

            Deal Size: $9.4 million Upfront Cash: Undisclosed

            Deal Type: Financing November 23, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Company introduces MC2 (melanocortin-2), a GPCR that binds to ACTH, aiming to develop an insurmountable antagonist with a best-in-class profile for rare endocrine disorders, including, Congenital Adrenal Hyperplasia and Cushing’s Disease.

            Lead Product(s): Undisclosed

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 04, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY